Role of common genetic variants in ovarian cancer susceptibility and outcome: Progress to date from the ovarian cancer association consortium (OCAC)

Journal of Internal Medicine

Volumn 271, Issue 4, 2012, Pages 366-378

  Bolton, K L ^a   Ganda, C ^b   Berchuck, A ^c   Pharaoh, P D P ^d   Gayther, S A ^e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Clinical outcome; Ovarian cancer; Susceptibility SNPs

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE; B RAF KINASE; BRCA1 PROTEIN; BRCA2 PROTEIN; CYTOCHROME P450 17; CYTOCHROME P450 3A4; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; INTERSTITIAL COLLAGENASE; K RAS PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; OLAPARIB; PROTEIN P53;

CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HISTOLOGY; HUMAN; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

FEMALE; FORECASTING; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 84858853451     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02509.x     Document Type: Review

References (102)

1. IARC.GLOBOCAN. Cancer incidence, mortality and prevalence worldwide (2002 estimates). 2002.
2. Stratton JF, Pharoah P, Smith SK, Easton D, Ponder BA. A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol 1998; 105: 493-9.
3. Lichtenstein P, Holm NV, Verkasalo PK et al. Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 78-85.
4. Antoniou AC, Pharoah PD, McMullan G et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer 2002; 86: 76-83.
5. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676-89.
6. Aarnio M, Sankila R, Pukkala E et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999; 81: 214-8.
7. Vasen HF, Stormorken A, Menko FH et al. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 2001; 19: 4074-80.
8. Watson P, Vasen HF, Mecklin JP et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 2008; 123: 444-9.
9. Meindl A, Hellebrand H, Wiek C et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010; 42: 410-4.
10. Szabo CI, King MC. Population genetics of BRCA1 and BRCA2. Am J Hum Genet 1997; 60: 1013-20.
11. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000; 19: 3-10.
12. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002; 31: 33-6.
13. Winter III WE, Maxwell GL, Tian C et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25: 3621-7.
14. Eisenhauer EA. Trial design for testing new therapies in ovarian cancer. Int J Gynecol Cancer 2005; 15(Suppl. 3): 258-65.
15. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351: 2519-29.
16. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
17. Park YG, Zhao X, Lesueur F et al. Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat Genet 2005; 37: 1055-62.
18. Lifsted T, Le VT, Williams M et al. Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int J Cancer 1998; 77: 640-4.
19. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
20. Bernards R, Weinberg RA. A progression puzzle. Nature 2002; 418: 823.
21. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
22. Takeuchi F, McGinnis R, Bourgeois S et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009; 5: e1000433.
23. Cooper GM, Johnson JA, Langaee TY et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008; 112: 1022-7.
24. Ochi H, Maekawa T, Abe H et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy - a genome-wide study of Japanese HCV virus patients. Gastroenterology 2010; 139: 1190-7.
25. Cha PC, Mushiroda T, Takahashi A et al. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum Mol Genet 2010; 19: 4735-44.
26. Teichert M, Eijgelsheim M, Rivadeneira F et al. A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet 2009; 18: 3758-68.
27. Shuldiner AR, O'Connell JR, Bliden KP et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849-57.
28. Suppiah V, Moldovan M, Ahlenstiel G et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
29. Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
30. Daly AK, Donaldson PT, Bhatnagar P et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41: 816-9.
31. Link E, Parish S, Armitage J et al. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med 2008; 359: 789-99.
32. Boyd J. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. J Am Med Assoc 2000; 283: 2260-5.
33. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol 2008; 26: 20-5.
34. Tan DS, Rothermundt C, Thomas K et al. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008; 26: 5530-6.
35. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003; 97: 2187-95.
36. Garcia-Closas M, Jacobs K, Kraft P, Chatterjee N. Analysis of epidemiological studies of genetic effects and gene-environment interactions. Molecular Epidemiology and Biomarkers: Principles and Practices. 2008.
37. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004; 96: 434-42.
38. Pharoah PD, Dunning AM, Ponder BA, Easton DF. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer 2004; 4: 850-60.
39. McKenna NJ, Kieback DG, Carney DN, Fanning M, McLinden J, Headon DR. A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma. Br J Cancer 1995; 71: 451-5.
40. Agoulnik IU, Tong XW, Fischer DC et al. A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk. J Clin Endocrinol Metab 2004; 89: 6340-7.
41. Berchuck A, Schildkraut JM, Wenham RM et al. Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers. Cancer Epidemiol Biomarkers Prev 2004; 13: 2141-7.
42. Lancaster JM, Berchuck A, Carney ME, Wiseman R, Taylor JA. Progesterone receptor gene polymorphism and risk for breast and ovarian cancer. Br J Cancer 1998; 78: 277.
43. Lancaster JM, Wenham RM, Halabi S et al. No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina. Cancer Epidemiol Biomarkers Prev 2003; 12: 226-7.
44. Leite DB, Junqueira MG, de Carvalho CV et al. Progesterone receptor (PROGINS) polymorphism and the risk of ovarian cancer. Steroids 2008; 73: 676-80.
45. Manolitsas TP, Englefield P, Eccles DM, Campbell IG. No association of a 306-bp insertion polymorphism in the progesterone receptor gene with ovarian and breast cancer. Br J Cancer 1997; 75: 1398-9.
46. Risch HA, Bale AE, Beck PA, Zheng W. PGR +331 A/G and increased risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 1738-41.
47. Romano A, Lindsey PJ, Fischer DC et al. Two functionally relevant polymorphisms in the human progesterone receptor gene (+331G/A and progins) and the predisposition for breast and/or ovarian cancer. Gynecol Oncol 2006; 101: 287-95.
48. Spurdle AB, Webb PM, Purdie DM, Chen X, Green A, Chenevix-Trench G. No significant association between progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of ovarian cancer. Carcinogenesis 2001; 22: 717-21.
49. Terry KL, De Vivo I, Titus-Ernstoff L, Sluss PM, Cramer DW. Genetic variation in the progesterone receptor gene and ovarian cancer risk. Am J Epidemiol 2005; 161: 442-51.
50. Tong D, Fabjani G, Heinze G, Obermair A, Leodolter S, Zeillinger R. Analysis of the human progesterone receptor gene polymorphism progins in Austrian ovarian carcinoma patients. Int J Cancer 2001; 95: 394-7.
51. Pearce CL, Hirschhorn JN, Wu AH et al. Clarifying the PROGINS allele association in ovarian and breast cancer risk: a haplotype-based analysis. J Natl Cancer Inst 2005; 97: 51-9.
52. Auranen A, Spurdle AB, Chen X et al. BRCA2 Arg372Hispolymorphism and epithelial ovarian cancer risk. Int J Cancer 2003; 103: 427-30.
53. Auranen A, Song H, Waterfall C et al. Polymorphisms in DNA repair genes and epithelial ovarian cancer risk. Int J Cancer 2005; 117: 611-8.
54. Beesley J, Jordan SJ, Spurdle AB et al. Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set. Cancer Epidemiol Biomarkers Prev 2007; 16: 2557-65.
55. Wenham RM, Schildkraut JM, McLean K et al. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer. Clin Cancer Res 2003; 9: 4396-403.
56. Bartel F, Jung J, Bohnke A et al. Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival. Clin Cancer Res 2008; 14: 89-96.
57. Fallows S, Price J, Atkinson RJ, Johnston PG, Hickey I, Russell SE. P53 mutation does not affect prognosis in ovarian epithelial malignancies. J Pathol 2001; 194: 68-75.
58. Buller RE, Sood A, Fullenkamp C, Sorosky J, Powills K, Anderson B. The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. Cancer Gene Ther 1997; 4: 239-45.
59. Gadducci A, Di Cristofano C, Zavaglia M et al. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome. Anticancer Res 2006; 26: 687-93.
60. Santos AM, Sousa H, Portela C et al. TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer. Biochem Biophys Res Commun 2006; 340: 256-62.
61. Reles A, Wen WH, Schmider A et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 2001; 7: 2984-97.
62. Hogdall EV, Kjaer SK, Glud E et al. Evaluation of a polymorphism in intron 2 of the p53 gene in ovarian cancer patients. From the Danish "Malova" Ovarian Cancer Study. Anticancer Res 2003; 23: 3397-404.
63. Beeghly A, Katsaros D, Chen H et al. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecol Oncol 2006; 100: 330-7.
64. Nagle CM, Chenevix-Trench G, Spurdle AB, Webb PM. The role of glutathione-S-transferase polymorphisms in ovarian cancer survival. Eur J Cancer 2007; 43: 283-90.
65. Medeiros R, Pereira D, Afonso N et al. Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. Int J Clin Oncol 2003; 8: 156-61.
66. Higashi T, Kyo S, Inoue M, Tanii H, Saijoh K. Novel functional single nucleotide polymorphisms in the latent transforming growth factor-beta binding protein-1L promoter: effect on latent transforming growth factor-beta binding protein-1L expression level and possible prognostic significance in ovarian cancer. J Mol Diagn 2006; 8: 342-50.
67. Obata H, Yahata T, Quan J, Sekine M, Tanaka K. Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer. Anticancer Res 2006; 26: 2227-32.
68. Pinto D, Pereira D, Portela C, da Silva JL, Lopes C, Medeiros R. The influence of HER2 genotypes as molecular markers in ovarian cancer outcome. Biochem Biophys Res Commun 2005; 335: 1173-8.
69. Six L, Grimm C, Leodolter S et al. A polymorphism in the matrix metalloproteinase-1 gene promoter is associated with the prognosis of patients with ovarian cancer. Gynecol Oncol 2006; 100: 506-10.
70. Song H, Hogdall E, Ramus SJ et al. Effects of common germ-line genetic variation in cell cycle genes on ovarian cancer survival. Clin Cancer Res 2008; 14: 1090-5.
71. Saldivar JS, Lu KH, Liang D et al. Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients. Gynecol Oncol 2007; 1(Suppl. 1): S223-9.
72. Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 2006; 12(3 Pt 1): 854-9.
73. Kang S, Ju W, Kim JW et al. Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Exp Mol Med 2006; 38: 320-4.
74. Li AJ, Lerner DL, Gapuzan ME, Karlan BY. AIB1 polymorphisms predict aggressive ovarian cancer phenotype. Cancer Epidemiol Biomarkers Prev 2005; 14: 2919-22.
75. Quaye L, Gayther SA, Ramus SJ et al. The effects of common genetic variants in oncogenes on ovarian cancer survival. Clin Cancer Res 2008; 14: 5833-9.
76. Smerdel MP, Waldstrom M, Brandslund I, Steffensen KD, Andersen RF, Jakobsen A. Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer. Int J Gynecol Cancer 2009; 19: 578-84.
77. Hefler LA, Mustea A, Konsgen D et al. Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. Clin Cancer Res 2007; 13: 898-901.
78. Steffensen KD, Waldstrom M, Brandslund I, Jakobsen A. The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol 2010; 117: 109-16.
79. Nagle CM, Chenevix-Trench G, Webb PM, Spurdle AB. Ovarian cancer survival and polymorphisms in hormone and DNA repair pathway genes. Cancer Lett 2007; 251: 96-104.
80. Ramus SJ, Vierkant RA, Johnatty SE et al. Consortium analysis of 7 candidate SNPs for ovarian cancer. Int J Cancer 2008; 123: 380-8.
81. Phelan CM, Tsai YY, Goode EL et al. Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 2010; 19: 600-4.
82. Pearce CL, Wu AH, Gayther SA et al. Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis. Br J Cancer 2008; 98: 282-8.
83. Lurie G, Wilkens LR, Thompson PJ et al. Vitamin D receptor rs2228570 polymorphism and invasive ovarian carcinoma risk: Pooled analysis in five studies within the Ovarian Cancer Association Consortium. Int J Cancer 2010; 128: 936-43.
84. Kelemen LE, Goodman MT, McGuire V et al. Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 2010; 19: 1822-30.
85. Schildkraut JM, Goode EL, Clyde MA et al. Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res 2009; 69: 2349-57.
86. Schildkraut JM, Iversen ES, Wilson MA et al. Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer. PLoS ONE 2010; 5: e10061.
87. Doherty JA, Rossing MA, Cushing-Haugen KL et al. ESR1/SYNE1 polymorphism and invasive epithelial ovarian cancer risk: an Ovarian Cancer Association Consortium study. Cancer Epidemiol Biomarkers Prev 2010; 19: 245-50.
88. Gayther SA, Song H, Ramus SJ et al. Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res 2007; 67: 3027-35.
89. Easton DF, Pooley KA, Dunning AM et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447: 1087-93.
90. Weedon MN, Lango H, Lindgren CM et al. Genome-wide association analysis identifies 20 loci that influence adult height. Nat Genet 2008; 40: 575-83.
91. Song H, Ramus SJ, Tyrer J et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 2009; 41: 996-1000.
92. Bolton KL, Tyrer J, Song H et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 2010; 42: 880-4.
93. Goode EL, Chenevix-Trench G, Song H et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 2010; 42: 874-9.
94. Antoniou AC, Wang X, Fredericksen ZS et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet 2010; 42: 885-92.
95. Donnelly P. Progress and challenges in genome-wide association studies in humans. Nature 2008; 456: 728-31.
96. Udler MS, Tyrer J, Easton DF. Evaluating the power to discriminate between highly correlated SNPs in genetic association studies. Genet Epidemiol 2010; 34: 463-8.
97. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-34.
98. Gelmon KA, Tischkowitz M, Mackay H et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011; 12: 852-61.
99. Pharoah PDP, Antoniou AC, Easton DF, Ponder BAJ. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 2008; 358: 2796-803.
100. Hawken SJ, Greenwood CM, Hudson TJ et al. The utility and predictive value of combinations of low penetrance genes for screening and risk prediction of colorectal cancer. Hum Genet 2010; 128: 89-101.
101. Park JH, Wacholder S, Gail MH et al. Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat Genet 2010; 42: 570-5.
102. 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 2010; 467: 1061-73.